Efficacy of Venetoclax in Combination With Rituximab in Waldenstr öm's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia Interventions: Drug: Venetoclax; Rituximab; Drug: DRC Sponsors: University of Ulm; Institute for Medical Informatics, Biometry and Epidemiology, University of Munich; Zentrum für Klinische Studien Ulm; AbbVie; Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Epidemiology | Macroglobulinemia | Pfizer | Research | Rituxan | Waldenstrom's Macroglobulinemia